Quince Therapeutics, Inc. 8-K

What Happened Quince Therapeutics, Inc. (QNCX) filed an 8-K reporting that Nasdaq notified the company on March 16–17, 2026 that it failed to meet two Nasdaq Global Select listing standards: the $1.00 minimum bid price and the $50,000,000 market value of listed securities (MVLS). The company has a 180‑day cure period for each deficiency — in both cases a compliance deadline of September 14, 2026 — to regain compliance (generally by meeting the required metric for at least ten consecutive business days). The notices do not cause immediate delisting and QNCX will continue trading on Nasdaq under the symbol “QNCX.”

Key Details

• March 16, 2026: Nasdaq notified QNCX that its closing bid price stayed below the $1.00 minimum for the last 30 consecutive business days; company has until September 14, 2026 to close at $1.00+ for at least ten consecutive business days (Nasdaq may require up to ~20 days).
• March 17, 2026: Nasdaq notified QNCX that its MVLS was below the $50,000,000 requirement for the last 30 consecutive business days; same September 14, 2026 compliance deadline and ten‑day standard.
• If QNCX does not regain compliance, it may be eligible to transfer listing to the Nasdaq Capital Market (subject to meeting other initial listing standards and paying fees) and could consider a reverse stock split as part of a cure.
• If Nasdaq moves to delist, the company may appeal to a Nasdaq Listing Qualifications Panel, but there is no assurance an appeal would succeed.

Why It Matters These notices indicate an elevated risk that QNCX could be moved off the Nasdaq Global Select Market if it does not restore the share price and/or market value within the cure periods. Delisting or a transfer to a different Nasdaq tier can reduce liquidity, limit investor access, and make it harder to raise capital. The company says it is monitoring the situation and will consider options to regain compliance, but there is no guarantee it will succeed.